Monoclonal Or Polyclonal Antibody Or Immunoglobulin Or Fragment Thereof That Is Conjugated Or Adsorbed (e.g., Adsorbed To A Solid Support, Etc.) Patents (Class 530/391.1)
Abstract: An immunoliposome composition targeted to the alphaV-integrin subunit of integrin receptors comprised of ligand-targeted liposomes bearing at least one targeting-ligand derived from an antibody and having binding specificity for at least one integrin receptor comprising an alpha V subunit including ?v?1, ?v?3 ?v?5, ?v?6, or ?v?8 integrin cell receptors is described. The antibody-derived targeting ligand may be a Fab? fragment, a scFv, or the like. Binding of the immunoliposome to ?v-integrin expressing cells, preferably results in internalization of the immunoliposome for cytoplasmic delivery of a liposome-entrapped agent.
Type:
Application
Filed:
May 11, 2011
Publication date:
November 3, 2011
Inventors:
Joshua Goldstein, Allen Magill, Deepak Saini, Linda A. Snyder, Raymond Sweet, Steve P. Weng
Abstract: A novel anti-human tenascin ST2146 monoclonal antibody is described endowed with high affinity with the native antigen and high tumor selectivity. The cST2146 hybridoma is stably producing the antibody in high density culture conditions and is suitable for the industrial development of ST2146-based products. ST2146 exhibits properties exploitable for both therapeutic and diagnostic applications.
Abstract: A compound of the general formula X-[Q-W—(CH?CH)n—(CH2)2-L]m (I) in which X represents a polymer; Q represents a linking group; W represents an electron-withdrawing group; n represents 0 or an integer of from 1 to 4; L represents a leaving group; and m represent an integer of from 1 to 8. The compounds find use in the conjugation of biological molecules.
Abstract: The invention generally relates to compositions and methods for isolating mid-log phase bacteria. In certain embodiments, the invention provides a magnetic particle conjugated to an antibody that includes an epitope specific for mid-log phase bacteria.
Abstract: An object to be solved by the present invention is to provide a highly reliable hazardous substance removing material capable of efficiently capturing and quickly inactivating hazardous substances of microbe origin such as viruses and bacteria, so as to minimize influences on the human body, such material being unlikely to be influenced by, for example, dimensional changes derived from dynamical and physical properties or a use environment (particularly humidity). The present invention provides a hazardous substance removing material which comprises a support having antibodies supported thereon, wherein a support is composed of a fiber which comprises at least one polymer having a carbonyl group and/or an ether group and has a volume swelling degree of not less than 1.1% to less than 10% in a water at 20° C.
Abstract: The invention generally relates to compositions that include sets of magnetic particles, members of each set being conjugated to an antibody specific for a pathogen.
Type:
Application
Filed:
April 21, 2011
Publication date:
October 27, 2011
Applicant:
NANOMR, INC.
Inventors:
Sergey A. Dryga, Victor C. Esch, Lisa-Jo Ann Clarizia, Eddie W. Adams, Thearith H. Ung, Ravil A. Sitdikov
Abstract: The present invention generally provides methods for the site-specific modification of peptides, polypeptides, and proteins, e.g., granulocyte macrophage colony-stimulating factor, human superoxide dismutase, annexin, leptin, antibodies and the like, cytokines and chemokines, at their N-termini and at sites at which unnatural aminoacids have been introduced along the protein framework. The modifications described herein can be used for the synthesis and application of the adducts in radio-labeling, molecular imaging and protein therapeutic applications, and the treatment of disorders such as rheumatoid arthritis, lupus erythematosus, psoriasis, multiple sclerosis, type-1 diabetes, Crohn's disease, and systemic sclerosis, Alzheimer disease, cancer, liver disease (e.g., alcoholic liver disease), and cachexia.
Abstract: The present invention provides an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80) and the antibody inhibits the binding of human IL-12 to human IL-12R ?2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12R?1.
Type:
Application
Filed:
August 14, 2009
Publication date:
October 27, 2011
Applicant:
CEPHALON AUSTRALIA PTY LTD.
Inventors:
Adam William Clarke, Anthony Gerard Doyle, Philip Jennings, Lynn Dorothy Poulton, Bernadette Wai, Andrew James Pow
Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.
Type:
Grant
Filed:
December 1, 2008
Date of Patent:
October 25, 2011
Assignee:
KaloBios Pharmaceuticals, Inc.
Inventors:
Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton, Mark Baer
Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.
Type:
Grant
Filed:
March 9, 2007
Date of Patent:
October 25, 2011
Assignee:
Wyeth LLC
Inventors:
Erwin R. Boghaert, Nitin K. Damle, Philip Ross Hamann, Kiran Khandke, Arthur Kunz, Kimberly A. Marquette, Lioudmila Tchistiakova, Davinder Gill, Kodangattil Sreekumar
Abstract: Disclosed herein are compositions and methods of use comprising hexavalent DNL complexes. Preferably, the complexes comprise anti-CD20 and/or anti-CD22 antibodies or fragments thereof. More preferably, the anti-CD20 antibody is veltuzumab and the anti-CD22 antibody is epratuzumab. Administration of the subject hexavalent DNL complexes induces apoptosis and cell death of target cells in diseases such as B-cell lymphomas or leukemias, autoimmune disease or immune dysfunction disease. In most preferred embodiments, the DNL complexes increase levels of phosphorylated p38 and PTEN, decrease levels of phosphorylated Lyn, Akt, ERK, IKK?/? and I?B?, increase expression of RKIP and Bax and decrease expression of Mcl-1, Bcl-xL, Bcl-2, and phospho-BAD in target cells. The subject DNL complexes show EC50 values for inhibiting tumor cell growth in the low nanomolar or even sub-nanomolar concentration range.
Type:
Application
Filed:
April 14, 2011
Publication date:
October 20, 2011
Applicant:
IMMUNOMEDICS, INC.
Inventors:
Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
Abstract: Described herein are methods, compositions and articles of manufacture involving neutral conjugated polymers including methods for synthesis of neutral conjugated water-soluble polymers with linkers along the polymer main chain structure and terminal end capping units. Such polymers may serve in the fabrication of novel optoelectronic devices and in the development of highly efficient biosensors. The invention further relates to the application of these polymers in assay methods.
Type:
Application
Filed:
March 17, 2011
Publication date:
October 20, 2011
Applicant:
Sirigen, Inc.
Inventors:
Brent S. Gaylord, Jean M. Wheeler, Glenn P. Bartholomew, Frank Peter Uckert, Janice W. Hong, William H. Huisman, Yongchao Liang
Abstract: Nucleic acids encoding erythropoietin isoforms are described herein, as well as the encoded isoforms, methods of detecting the same, and methods of screening for and treating cancer.
Abstract: A method for the manufacture of at least one sorbent having at least two different groups, which are capable of binding, for the selective binding of a substrate, characterized in that it comprises the steps (i) to (ii): (i) determining at least two groups capable of binding a sorbent from a synthetic or natural first substrate, (ii) respectively applying at least two different groups capable of binding a second synthetic or natural substrate to one respective carrier, thereby forming at least one sorbent, whereby the groups are the same groups of step (i) or are groups that are complementary thereto, and the second substrate of step (ii) is the same or different from the first substrate according to step (i), and whereby the groups are determined such that the contributions of the Gibbs energies of the individual groups to the non-covalent bond with the second substrate yield a negative value of the Gibbs energy ?G, such that a binding strengthening occurs that results in an improved separation selectivity
Abstract: Described herein is the use of antibody-based delivery agents to target and deliver nucleic acid agents into specific cell types. Herein, we describe methods used that improve the ability of conjugates that load over 3 siRNA per conjugate and target siRNA to cells expressing the appropriate cell surface antigens. We also contemplate the use of antibody, targeting peptides, small molecules, aptamers and all other factors known in the art that can specifically target tissues. In each case, these targeting moieties can be conjugated using chemical crosslinking agents to carriers enabling directed delivery of nucleic acids.
Type:
Application
Filed:
February 11, 2009
Publication date:
October 20, 2011
Inventors:
Lance P. Ford, Joe Krebs, Brittan L. Pasloske
Abstract: Isolated polypeptides, isolated polynucleotides or expression vectors encoding same, viral display vehicles which can be specifically bind an exposed epitope shared by mutant, but not wild type, p53 protein are provided. Also provided are methods of inducing apoptosis and treating cancer as well as diagnosing a p53-related cancer using the isolated polypeptides uncovered by the present invention.
Type:
Grant
Filed:
March 23, 2006
Date of Patent:
October 18, 2011
Assignee:
Ramot at Tel-Aviv University Ltd.
Inventors:
Beka Solomon, Sara Orgad, Itai Benhar, Ronit Rosenfeld
Abstract: The present invention dedicates to detect nephritis in early stage of either primary or secondary nephritis using an anti NC1 monoclonal antibody. The present invention dedicates to provide useful information for diagnosis of renal function to detect NC1 by immunofluorescent stain method in renal biopsy section obtained at early stage where immunoglobulins do not deposit yet in renal GBM etc, or by antigen-antibody reaction in urine or serum specimens. Furthermore, the present invention comprises to utilize for therapeutic use.
Abstract: Antibodies and molecules derived therefrom that bind to 24P4C12 protein and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 24P4C12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 24P4C12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 24P4C12 can be used in active or passive immunization.
Type:
Grant
Filed:
September 5, 2008
Date of Patent:
October 18, 2011
Assignee:
Agensys, Inc.
Inventors:
Arthur B. Raitano, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Steven B. Kanner, Pia M. Challita-Eid, Xiao-chi Jia, Jean Gudas, Aya Jakobovits
Abstract: The present invention relates to Fc variants with optimized properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized properties, and methods for using Fc variants with optimized properties.
Type:
Application
Filed:
May 6, 2011
Publication date:
October 13, 2011
Applicant:
Xencor, Inc.
Inventors:
Gregory Alan Lazar, Wei Dang, John R. Desjarlais, Sher Bahadur Karki
Abstract: The present invention discloses compositions and methods for delivery of biomolecules into cells. Compositions comprise peptidomimetic macrocycles complexed or conjugated to biomolecules such as nucleic acids.
Abstract: TSG101 is a tumor susceptibility gene whose homozygous functional knock out in fibroblasts leads to transformation and the ability of these cells to form metastatic tumors in nude mice. The cellular transformation that results from inactivation of TSG101 is reversible by restoration of TSG101 function. Decreased expression of TSG101 is associated with the occurrence of certain human cancers, including breast carcinomas. The TSG101 nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as treatment of cancer, identification of cell type based on expression, and the like.
Abstract: Immunoglobulins which each have one or more amino acid modifications in at least one structural loop region of such immunoglobulins, where the modified loop region specifically binds to an epitope of an antigen to which an unmodified immunoglobulin does not significantly bind, obtained from display libraries.
Abstract: The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In more preferred embodiment the cytokine is G-CSF, erythropoietin or INF-?2b.
Type:
Grant
Filed:
April 1, 2010
Date of Patent:
October 11, 2011
Assignee:
IBC Pharmaceuticals, Inc.
Inventors:
Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
Abstract: Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.
Type:
Grant
Filed:
November 7, 2008
Date of Patent:
October 11, 2011
Assignees:
Affitech Research, AS, Peregrine Pharmaceuticals, Inc.
Abstract: The present invention relates to specific delivery of agrochemicals to plants. More specifically, it relates to a composition, essentially consisting of a targeting agent comprising at least one binding domain that specifically binds to a binding site on an intact living plant and an agrochemical or a combination of agrochemicals. The present invention relates further to a binding domain that specifically binds the binding site on an intact living plant. More specifically, it relates to binding domains comprising an amino acid sequence that comprises four framework regions and three complementary determining regions, or any suitable fragment thereof, whereby the binding domains are capable to bind or retain a carrier onto a plant. In one preferred embodiment, the invention relates to binding domains which specifically bind trichomes, stomata, cuticle, lenticels, thorns, spines, root hairs, or wax layer.
Abstract: The present disclosure provides photoactive polypeptides. A subject photoactive polypeptide is useful in a variety of applications, which are also provided.
Type:
Application
Filed:
March 31, 2011
Publication date:
October 6, 2011
Inventors:
Michael A. Marletta, Michael B. Winter, Emily J. McLaurin, Steven Y. Reece, Charles Olea, JR., Daniel G. Nocera
Abstract: The invention provides monoclonal antibodies that neutralize TNF? activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNF? activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications.
Type:
Application
Filed:
April 29, 2011
Publication date:
October 6, 2011
Inventors:
FERNANDO JOSE REBELO DO COUTO, KRISTIN BETH HENDRICKS, STACEY ELLEN WALLACE
Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
Type:
Application
Filed:
May 31, 2011
Publication date:
October 6, 2011
Applicant:
Schering Corporation
Inventors:
Madaline Chirica, Robert A. Kastelein, Kevin W. Moore, Christi L. Parham
Abstract: The present invention relates to novel Fc variants that comprise at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc receptor or ligand (e.g., Fc gamma R, C1q). Additionally, the Fc variants have altered complement dependent cytotoxicity (CDC) activity and/or antibody-dependent cell-mediated cytotoxicity (ADCC). The invention further provides methods and protocols for the application of said Fc variants, particularly for therapeutic purposes.
Type:
Application
Filed:
January 19, 2011
Publication date:
September 29, 2011
Applicant:
XENCOR, INC.
Inventors:
Gregory A. Lazar, Sher Bahadur Karki, Gregory L. Moore
Abstract: Disclosed are ligands that have binding specificity for interleukin-13 (IL-13), or for IL-4 and IL-13. Also disclosed are methods of using these ligands. In particular, the use of these ligands for treating IL-13-mediated conditions, such as lung conditions, eg allergic asthma, is described. The ligands have potent IL-13 binding kinetics. Ligands are described that are cross-reactive between human IL-13 and one or more primate IL-13. Ligands are well expressed in prokaryotic cells.
Type:
Application
Filed:
December 17, 2008
Publication date:
September 29, 2011
Inventors:
Rudolf M. T. De Wildt, Inusha De Silva, Milan Ovecka
Abstract: The invention provides a method for introducing 1,4,7,10-tetraazacyclododecane-N,N?,N?,N??-tetraacetic acid (DOTA) into a compound such as a peptide. The method comprises a first step for preparing a mixed liquid of DOTA having no protecting group and dimethylsulfoxide, and a second step for contacting the mixed liquid with the compound carried on a solid-phase carrier.
Abstract: The invention relates to sample analysis work flows for increasing the efficiency of experiments. Compositions and methods are described for selectively increase the abundance of methylated nucleic acid over non-methylated nucleic acid, followed by analysis of the nucleic acid to identify methylation sites.
Type:
Application
Filed:
November 19, 2010
Publication date:
September 29, 2011
Applicant:
LIFE TECHNOLOGIES CORPORATION
Inventors:
Kevin Clancy, Gavin Meredith, Christopher Adams, Daniel Krissinger
Abstract: Interleukin-17A (IL-17A) antibody antagonists, polynucleotides encoding IL-17A antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.
Type:
Application
Filed:
October 29, 2010
Publication date:
September 29, 2011
Inventors:
Juan Carlos Almagro, Daniela Della Ducata, Merle Elloso, Jinquan Luo, Thomas Malia, Michael Naso, Galina Obmolova, Robert Rauchenberger, Mark Rutz, Raymond Sweet, Susann Taudte, Bingyuan Wu, Sheng-Jiun Wu
Abstract: An antibody-fragment-immobilizing substrate includes a substrate and at least one set of antibody fragments, wherein the antibody fragments of each set includes at least two types of separate antibody fragments that are capable of recognizing one type of antigen and that are independently immobilized on the substrate in a positional relationship that allows each of the antibody fragments in one set to bind to the same antigen.
Type:
Application
Filed:
October 23, 2009
Publication date:
September 29, 2011
Applicants:
FUJIFILM Corporation, THE UNIVERSITY OF TOKYO
Abstract: The present invention relates generally to novel peptides and related compounds that have thrombopoietic activity. The compounds of the invention may be used to increase production of platelets or platelet precursors (e.g. megakaryocytes) in a mammal.
Type:
Application
Filed:
December 22, 2010
Publication date:
September 22, 2011
Applicant:
Amgen Inc.
Inventors:
Hosung Min, Karen C. Sitney, Cynthia Hartley
Abstract: The present invention is based on the identification of synaptic vessel glycoprotein SV2 as the BoNT/A receptor and the further identification of various BoNT/A-binding fragments of SV2. The disclosure here provides new tools for diagnosing and treating botulism.
Abstract: Provided herein are targetable constructs that are multivalent carriers of bi-specific antibodies, i.e., each molecule of a targetable construct can serve as a carrier of two or more bi-specific antibodies. Also provided are targetable complexes formed by the association of a targetable construct with two or more bi-specific antibodies. The targetable constructs and targetable complexes of the invention are incorporated into biosensors, kits and pharmaceutical compositions, and are used in a variety of therapeutic and other methods.
Type:
Application
Filed:
April 19, 2011
Publication date:
September 15, 2011
Applicant:
IMMUNOMEDICS, INC.
Inventors:
Hans J. Hansen, William J. McBride, Zhengxing Qu
Abstract: DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.
Type:
Application
Filed:
March 1, 2011
Publication date:
September 8, 2011
Applicant:
ABBOTT LABORATORIES
Inventors:
Ming-Jiu Chen, Chung-Ming Hsieh, Jijie Gu, Susan E. Morgan-Lappe, Yingchun Li
Abstract: Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.
Type:
Grant
Filed:
March 4, 2009
Date of Patent:
September 6, 2011
Assignee:
Agensys, Inc.
Inventors:
Jean Gudas, Aya Jakobovits, Xiao-chi Jia, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Hui Shao, Pia M. Challita-Eid, Arthur B. Raitano
Abstract: A novel gene (designated 84P2A9) and its encoded protein is described. While 84P2A9 exhibits prostate and testis specific expression in normal adult tissue, it is aberrantly expressed multiple cancers including prostate, testis, kidney, brain, bone, skin, ovarian, breast, pancreas, colon, lymphocytic and lung cancers. Consequently, 84P2A9 provides a diagnostic and/or therapeutic target for cancers, and the 84P2A9 gene or fragment thereof, or its encoded protein or a fragment thereof used to elicit an immune response.
Type:
Grant
Filed:
November 26, 2008
Date of Patent:
September 6, 2011
Assignee:
Agensys, Inc.
Inventors:
Aya Jakobovits, Daniel E. H. Afar, Pia M. Challita-Eid, Elana Levin, Steve Chappell Mitchell, Rene S. Hubert
Abstract: Presented herein are biomarkers related to breast cancer. The presently identified salivary biomarkers create the basis for a breast cancer detection bioassay with sensitivity and specificity. Means and methods for evaluating the data generated using multiple biomarkers in order to validate findings and further use of the multiplexed breast cancer assay in clinical, diagnostic and therapeutic uses is also included.
Type:
Application
Filed:
February 10, 2011
Publication date:
September 1, 2011
Applicant:
The Regents of the University of California
Inventors:
David T. WONG, Lei Zhang, Hua Xiao, Hui Zhou
Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
Type:
Application
Filed:
October 28, 2010
Publication date:
September 1, 2011
Applicant:
ABBOTT LABORATORIES
Inventors:
Tariq Ghayur, Jochen G. Salfeld, Michael J. McPherson, Maria C. Harris, Junjian Liu, Peter C. Isakson, Jijie Gu
Abstract: Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. An appropriate amino acid residue for conjugation may be present in a native Fc domain at the conjugation site or may be added by insertion (i.e., between amino acids in the native Fc domain) or by replacement (i.e., removing amino acids and substituting different amino acids). In the latter case, the number of amino acids added need not correspond to the number of amino acids removed from the previously existing Fc domain. This technology may be used to produce useful compositions of matter and pharmaceutical compositions containing them.
Type:
Grant
Filed:
August 10, 2006
Date of Patent:
August 30, 2011
Assignee:
Amgen Inc.
Inventors:
Colin V. Gegg, Kenneth W. Walker, Leslie P. Miranda, Fei Xiong
Abstract: The present invention concerns a method for the preparation of molecular conjugates comprising immunoglobulins and biomarkers occurring in neoplastic diseases characterized by high levels of reproducibility.
Type:
Application
Filed:
October 13, 2008
Publication date:
August 25, 2011
Applicant:
XEPTAGEN SPA
Inventors:
Paolo Pengo, Luca Beneduce, Giorgio Fassina
Abstract: DNA dendrimers for targeted delivery of radiation absorbing nanoparticles and thermal ablation of cells and tissues are provided. Also provided are methods of making and methods of using the DNA dendrimers.
Abstract: Biologically active compounds are provided that can be used as photosensitizers for diagnostic and therapeutic applications, particularly for PDT of cancer, infections and other hyperproliferative diseases, fluorescence diagnosis and PDT treatment of a non-tumorous indication such as arthritis, inflammatory diseases, viral or bacterial infections, dermatological, ophthalmological or urological disorders as well as providing methods to obtain them in pharmaceutical quality. One embodiment consists of a method to synthesize a porphyrin with a defined arrangement of meso-substituents and then converting this porphyrin system to a chlorin system by dihydroxylation or reduction, and if more than one isomer is formed separate them by chromatography either on normal or reversed phase silica. In another embodiment the substituents on the porphyrin are selected to direct the reduction or dihydroxylation to the chlorin so that a certain isomer is selectively formed.
Type:
Application
Filed:
September 17, 2009
Publication date:
August 25, 2011
Inventors:
Arno Wiehe, Daniel Aicher, Christian B .W. Stark, Volker Albrechi, Susanna Gräfe
Abstract: Presented herein are biomarkers related to lung cancer. The presently identified salivary biomarkers create the basis for a lung cancer detection bioassay with sensitivity and specificity. Means and methods for evaluating the data generated using multiple biomarkers in order to validate findings and further use of the multiplexed lung cancer assay in clinical, diagnostic and therapeutic uses is also included.
Type:
Application
Filed:
February 10, 2011
Publication date:
August 25, 2011
Applicant:
The Regents of the University of California
Inventors:
David T. WONG, Lei Zhang, Hua Xiao, Hui Zhou
Abstract: In one aspect, the present invention relates to an antigen-binding molecule specific for albumin and CD3 which may comprise two polypeptide chains, each polypeptide chain having at least four variable domains in an orientation preventing Fv formation and the two polypeptide chains are dimerized with one another thereby forming a multivalent antigen-binding molecule. On each of the two polypeptide chains the four variable domains may be arranged in the order VLA-VHB-VLB-VHA from the N-terminal to the C-terminal of the polypeptide. Compositions of the antigen-binding molecule and the methods of using the antigen-binding molecule or the compositions thereof for treatment of various diseases are also provided herein.
Abstract: The C-terminal domain of focal adhesion kinase (FAK-CD) was isolated using a Baculoviral system. Using phage display techniques, a phage encoding a 12 amino-acid peptide (peptide 35) and AV3 that binds to FAK-CD were identified. The peptides were also conjugated to TAT-FITC to produce a fluorescently labeled chimeric molecule capable of penetrating cell membranes. Contacting various breast cancer cell lines with these molecule caused detachment, rounding, apoptosis and cell death. These effects were not observed in normal (non-cancerous) breast cells.
Type:
Grant
Filed:
November 17, 2004
Date of Patent:
August 23, 2011
Assignee:
University of Florida Research Foundation, Inc.
Inventors:
William G. Cance, Vita Golubovskaya, Elena V. Kurenova
Abstract: Fluorescent, sulfonated 3,7-diamino-[8,9]benzophenoxazine dyes are provided that are especially useful for labelling biopolymers and other substrates. The dye-labelled conjugates can be used in a variety of contexts, including cell surface assays employing intact, live cells and in nucleic acid detection methods. The new dyes are water soluble and can be conjugated to a variety of substrates, such as polynucleotides, nucleosides, nucleotides, peptides, proteins, antibodies, carbohydrates, ligands, particles and surfaces.